Herpes Zoster (Shingles): Molecular Pathogenesis, Immune Mechanisms, Clinical Manifestations, Therapeutic Advances, and Prevention Strategies – A Comprehensive Review
Downloads
The latent varicella-zoster virus (VZV), a member of the Herpesviridae family, reactivates to cause herpes zoster (HZ), sometimes referred to as shingles, a neurocutaneous illness. VZV creates a lifetime delay inside sensory ganglia after primary infection, which typically presents as varicella (chickenpox). When VZV-specific cellular immunity decreases, especially with aging, immunosuppression, or long-term medical problems, the virus reactivates. The clinical presentation of herpes zoster is characterised by unilateral dermatomal pain followed by a vesicular skin eruption; however, severe complications such as postherpetic neuralgia (PHN), ophthalmic involvement, neurological disorders, and disseminated infection may occur.Recent advances have improved understanding of the molecular mechanisms involved in VZV latency, immune regulation, neuroinflammation, and chronic pain development. Antiviral therapies, including acyclovir, valacyclovir, and famciclovir, remain the mainstay of treatment, particularly when initiated early. In addition, recombinant zoster vaccines have significantly improved prevention strategies, especially among older adults and immunocompromised individuals. This review summarizes current knowledge regarding VZV biology, epidemiology, pathogenesis, immune responses, clinical manifestations, diagnosis, treatment approaches, and recent preventive strategies. Understanding the complex interaction between viral persistence and host immunity is essential for improving disease management and reducing herpes zoster-associated morbidity.
[1] T. C. Heineman, A. Cunningham, and M. Levin, “Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine,” Current Opinion in Immunology, vol. 59, pp. 42–48, Aug. 2019.
[2] D. Watanabe, “Cutaneous herpesvirus infection,” Brain and Nerve, vol. 71, no. 4, pp. 302–308, Apr. 2019.
[3] Y. H. Yu, Y. Lin, and P. J. Sun, “Segmental zoster abdominal paresis mimicking an abdominal hernia: A case report and literature review,” Medicine, vol. 98, no. 15, Art. no. e15037, Apr. 2019.
[4] H. Senderovich, J. Grewal, and M. Mujtaba, “Herpes zoster vaccination efficacy in the long-term care facility population: A qualitative systematic review,” Current Medical Research and Opinion, vol. 35, no. 8, pp. 1451–1462, Aug. 2019.
[5] C. Warren-Gash et al., “Human herpesvirus infections and dementia or mild cognitive impairment: A systematic review and meta-analysis,” Scientific Reports, vol. 9, no. 1, Art. no. 4743, Mar. 18, 2019.
[6] A. R. Davis and J. Sheppard, “Herpes zoster ophthalmicus review and prevention,” Eye & Contact Lens, vol. 45, no. 5, pp. 286–291, Sep. 2019.
[7] E. Baumrin et al., “A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, vol. 81, no. 1, pp. 102–110, Jul. 2019.
[8] L. W. Miles, N. Williams, K. E. Luthy, and L. Eden, “Adult vaccination rates in the mentally ill population: An outpatient improvement project,” Journal of the American Psychiatric Nurses Association, vol. 26, no. 2, pp. 172–180, Mar.–Apr. 2020.
[9] B. V. Rooney, B. E. Crucian, D. L. Pierson, M. L. Laudenslager, and S. K. Mehta, “Herpes virus reactivation in astronauts during spaceflight and its application on Earth,” Frontiers in Microbiology, vol. 10, Art. no. 16, 2019.
[10] L. P. Hurley et al., “Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV),” Vaccine, vol. 36, no. 48, pp. 7408–7414, Nov. 19, 2018.
[11] Y. Y. Syed, “Recombinant zoster vaccine (Shingrix®): A review in herpes zoster,” Drugs & Aging, vol. 35, no. 12, pp. 1031–1040, Dec. 2018.
[12] C. M. Mospan and N. Colvin, “What are the new vaccination recommendations for herpes zoster?” JAAPA, vol. 31, no. 10, pp. 14–15, Oct. 2018.
[13] K. L. Hawkins et al., “Herpes zoster and herpes zoster vaccine rates among adults living with and without HIV in the Veterans Aging Cohort Study,” Journal of Acquired Immune Deficiency Syndromes, vol. 79, no. 4, pp. 527–533, Dec. 1, 2018.
[14] H. Liu et al., “Research progress on varicella-zoster virus vaccines,” Vaccines, vol. 13, Art. no. 730, 2025.
[15] W. Gao, D. Gao, L. Li, et al., “Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024,” Frontiers in Medicine, vol. 12, Art. no. 1516450, 2025.
[16] J. Chen, P. E. Abrahamson, Y. Ke, et al., “A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific,” Human Vaccines & Immunotherapeutics, vol. 20, no. 1, Art. no. 2344983, 2024.
[17] Y. L. Lin, S. I. Wang, and J. C. Wei, “Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: A retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network,” eClinicalMedicine, vol. 85, Art. no. 103319, 2025.
[18] C. X. Pan, M. S. Lee, and V. E. Nambudiri, “Global herpes zoster incidence, burden of disease, and vaccine availability: A narrative review,” Therapeutic Advances in Vaccines and Immunotherapy, vol. 10, Art. no. 25151355221084535, 2022.
[19] J. Breuer, “Molecular genetic insights into varicella zoster virus (VZV), the vOka vaccine strain, and the pathogenesis of latency and reactivation,” Journal of Infectious Diseases, vol. 218, suppl. 2, pp. S75–S80, 2018.
[20] W. J. D. Ouwendijk, D. P. Depledge, L. Rajbhandari, et al., “Varicella-zoster virus VLT-ORF63 fusion transcript induces broad viral gene expression during reactivation from neuronal latency,” Nature Communications, vol. 11, no. 1, Art. no. 6324, 2020.
[21] J. Hertzog, W. Zhou, G. Fowler, et al., “Varicella-zoster virus ORF9 is an antagonist of the DNA sensor cGAS,” The EMBO Journal, vol. 41, no. 14, Art. no. e109217, 2022.
[22] X. Che, S. L. Oliver, M. Reichelt, et al., “ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection,” Journal of Virology, vol. 87, no. 9, pp. 5106–5117, 2013.
[23] V. Girault, A. Stukalov, M. E. Carter-Timofte, et al., “Multi-proteomic profiling of the varicella-zoster virus–host interface reveals host susceptibilities to severe infection,” Nature Microbiology, vol. 10, no. 8, pp. 2048–2072, 2025.
[24] D. P. Depledge, T. Sadaoka, and W. J. D. Ouwendijk, “Molecular aspects of varicella-zoster virus latency,” Viruses, vol. 10, no. 7, 2018.
[25] H. Liu et al., “Research progress on varicella-zoster virus vaccines,” Vaccines, vol. 13, Art. no. 730, 2025.
[26] W. Gao, D. Gao, L. Li, et al., “Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024,” Frontiers in Medicine, vol. 12, Art. no. 1516450, 2025.
[27] J. Chen, P. E. Abrahamson, Y. Ke, et al., “A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific,” Human Vaccines & Immunotherapeutics, vol. 20, no. 1, Art. no. 2344983, 2024.
[28] Y. L. Lin, S. I. Wang, and J. C. Wei, “Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: A retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network,” eClinicalMedicine, vol. 85, Art. no. 103319, 2025.
[29] C. X. Pan, M. S. Lee, and V. E. Nambudiri, “Global herpes zoster incidence, burden of disease, and vaccine availability: A narrative review,” Therapeutic Advances in Vaccines and Immunotherapy, vol. 10, Art. no. 25151355221084535, 2022.
[30] J. Breuer, “Molecular genetic insights into varicella zoster virus (VZV), the vOka vaccine strain, and the pathogenesis of latency and reactivation,” Journal of Infectious Diseases, vol. 218, suppl. 2, pp. S75–S80, 2018.
[31] W. J. D. Ouwendijk, D. P. Depledge, L. Rajbhandari, et al., “Varicella-zoster virus VLT-ORF63 fusion transcript induces broad viral gene expression during reactivation from neuronal latency,” Nature Communications, vol. 11, no. 1, Art. no. 6324, 2020.
[32] J. Hertzog, W. Zhou, G. Fowler, et al., “Varicella-zoster virus ORF9 is an antagonist of the DNA sensor cGAS,” The EMBO Journal, vol. 41, no. 14, Art. no. e109217, 2022.
[33] X. Che, S. L. Oliver, M. Reichelt, et al., “ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection,” Journal of Virology, vol. 87, no. 9, pp. 5106–5117, 2013.
[34] V. Girault, A. Stukalov, M. E. Carter-Timofte, et al., “Multi-proteomic profiling of the varicella-zoster virus–host interface reveals host susceptibilities to severe infection,” Nature Microbiology, vol. 10, no. 8, pp. 2048–2072, 2025.
[35] D. P. Depledge, T. Sadaoka, and W. J. D. Ouwendijk, “Molecular aspects of varicella-zoster virus latency,” Viruses, vol. 10, no. 7, 2018.

